Sanofi-Aventis SA (ADR) (NYSE:SNY), France’s biggest pharmaceutical group has accused Hospira Inc and Canada’s Apotex Inc of infringing patents for the cancer drug Taxotere. Sanofi-Aventis has said that both the companies have tried to copy their products. Earlier Sanofi-Aventis have filed separate complaints against Hospira Inc and Apotex Inc that they have violated the patent laws and have attempted to duplicate their top ranging product that is developed and marketed for the treatment of cancer patients. Though the market reacted sharply after the news broke into the market, but there was not much of fluctuation in the shares of Sanofi-Aventis at the end of the day.

Sanofi-Aventis is one of the leading pharmaceutical companies in France and globally as well. The company is into the research, development, manufacturing

...

For Immediate Release

Chicago, IL – September 21, 2009 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Lennar Corporation (LEN), VeriChip (CHIP), Sanofi-Aventis SA (SFY), AstraZeneca (AZN) and Novartis AG (NOV).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Monday's Analyst Blog:

Lennar Predicts Profit in 2010

Lennar Corporation (LEN) one of the nation's largest home builders, predicts a return to profitability in 2010 as it targets the hot market of first time homebuyers and those looking for more bang for their buck.

The company reported third-quarter results today which surprised on the

...

An announcement today regarding the exclusive license granted to controversial chip-implant maker VeriChip (CHIP) for H1N1 detection sent CHIP shares hurtling nearly out of orbit -- up 178%, or over $2 per share -- to around $3.20 by Monday afternoon. Other news reports have cited that this is the biggest intra-day gain since the company went public in February 2007. VeriChip's development partner, RECEPTORS LLC, has granted exclusive rights to VeriChip to develop one of its patents based on the "virus triage detection system" used to treat H1N1 virus, commonly known as "swine flu." The H1N1 virus sent shockwaves of worry about a dangerous pandemic developing world-wide, and just last week came FDA approval of the first treatments of the virus from Sanofi-Aventis SA (SFY), CSL Ltd, MedImmune (now a subsidiary of AstraZeneca AZN) and Novartis AG (NOV). VeriChip is best known for ...

Here are the stocks added to the Zacks #1 Rank ("strong buy") List today:

AMCOL International Corp (ACO) Apollo Group Inc (APOL) Atmel Corp (ATML) Bayer AG (BAYRY) BioDelivery Sciences International Inc (BDSI) British American Tobacco (BTI) Cadbury Plc (CBY) Celanese Corp (CE) Central European Media Enterprises Ltd (CETV) CRH Plc (CRH) Diageo Plc (DEO) First Bancorp (FBNC) Flamel Technologies SA (FLML) Flanders Corp (FLDR) Grupo Televisa SA (TV) HDFC Bank Ltd (HDB) Henkel AG (HENKY) Herbalife Ltd (HLF) Jefferies Group Inc (JEF) Jones Apparel Group Inc (JNY) L'Oreal SA (LRLCY) Longtop Financial Technologies Ltd (LFT) MFA Financial Inc (MFA) MTR Gaming Group Inc (MNTG) Multi-Color Corp (LABL) National Australia Bank Ltd (NABZY) Odyssey Re Holdings Corp (ORH) Orbitz Worldwide Inc (...

Here are the stocks added to the Zacks #1 Rank ("strong buy") List today:

Aluminum Corp of China Ltd (ACH) Associated British Foods Plc (ASBFY) Compania Cervecerias Unidas SA (CCU) Check Point Software Technologies Ltd (CHKP) Comcast Corp (CMCSK) Corrections Corporation of America (CXW) DeVry Inc (DV) Dollar Tree Inc (DLTR) ITT Educational Services Inc (ESI) Jones Apparel Group Inc (JNY) Mead Johnson Nutrition Co (MJN) Northrim BanCorp Inc (NRIM) O'Reilly Automotive Inc (ORLY) Perdigao SA (PDA) Rent-A-Center Inc (RCII) Sanofi-Aventis SA (SNY) Shore Bancshares Inc (SHBI) Universal Electronics Inc (UEIC) WestAmerica Bancorp (WABC) Williams-Sonoma Inc (WSM)View the entire Zacks #1 Rank List.

"ACH" Free Stock Analysis: Buy? Sell? Hold?"ASBFY" Free Stock Analysis: Buy? Sell? Hold?"CCU" Free Stock Analysis: Buy? ...

Here are the stocks added to the Zacks #1 Rank ("strong buy") List today:

The AES Corp (AES) Michael Baker Corp (BKR) Ctrip.com International Ltd (CTRP) Huaneng Power International Inc (HNP) POSCO (PKX) Sanofi-Aventis SA (SNY) Telefonica SA (TEF) UGI Corp (UGI) Westpac Banking Corp (WBK) WMS Industries Inc (WMS) View the entire Zacks #1 Rank List.

"AES" Free Stock Analysis: Buy? Sell? Hold?"BKR" Free Stock Analysis: Buy? Sell? Hold?"CTRP" Free Stock Analysis: Buy? Sell? Hold?"HNP" Free Stock Analysis: Buy? Sell? Hold?"PKX" Free Stock Analysis: Buy? Sell? Hold?"SNY" Free Stock Analysis: Buy? Sell? Hold?"TEF" Free Stock Analysis: Buy? Sell? Hold?"UGI" Free Stock Analysis: Buy? Sell? Hold?"WBK" Free Stock Analysis: Buy? Sell? Hold?"WMS" Free Stock Analysis: Buy? ...

Krugman: U.S. in Danger of Lost Decade; Trichet Sees First Signs of Recovery; Plavix Could Have Serious Competitor; Intel Could Face Record Antitrust Fine; GM Open to Leaving Detroit; Microsoft in First Bond Offering; Dish Network Beats Expectations; Nortel Blows a Fuse

Nobel Prize-winning economist Paul Krugman said the United States needs to take aggressive economy-stimulating action or risk facing a lost decade of growth a la Japan in the 1990s. “We’re doing half-measures that help the economy limp along without fully recovering, and we’re having measures that help the banks survive without really thriving,” Krugman told reporters in Beijing, Reuters reported. “We’re doing what the Japanese did in the 90s.” European Central Bank President Jean-Claude Trichet said he and fellow policy makers are ...

Highlights include AstraZeneca plc (AZN), Bristol-Myers Squibb Company (BMY), Sanofi-Aventis SA (SNY) and Eli Lilly and Company (LLY).Brilinta Not AstraZeneca's PanaceaThis morning, AstraZeneca (AZN) announced positive top-line results of its phase III 18,600-patient PLATO trial, comparing AZN's Brilinta (ticagrelor) with Plavix (clopidogrel) in the reduction of cardiovascular events in patients with acute coronary syndrome (i.e. - at-risk of cardiovascular events).The company announced that Brilinta met the primary endpoint in the trial, a statistically significant difference in time to occurrence of any event of the composite endpoint of myocardial infarction, stroke or cardiovascular death. Safety was comparable to what was observed in phase II trials.The full-results of the trial are expected to be presented at the annual European Society of Cardiology meeting in August. AstraZeneca expects to submit Brilinta for FDA approval in the fourth quarter 2009, potentially ...

We highlight Acorda Therapeutics, Inc. (ACOR), Biogen Idec, Inc. (BIIB), Pfizer, Inc. (PFE), Sanofi-Aventis SA (SNY) and Wyeth (WYE).We upgraded shares of Acorda Therapeutics, Inc. (ACOR) the day after the FDA issued the RTF ("refuse to file") letter on April 1, 2009. At that time the shares were hit hard -- down to the $18 level -- and we noted that we "Finally got our buying opportunity." We previously had a Hold rating on the name, waiting for a pullback before we recommended clients get in.Over the past few months we have become increasingly confident that the application for Fampridine-SR looks strong -- from a clinical data standpoint. The application contains data from a comprehensive development program assessing the safety and efficacy of Fampridine-SR, including two phase III trials that involved 540 people with MS and were conducted under Special ...

For Immediate Release

Chicago, IL - May 1, 2009 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: L-3 Communications (LLL), Wyeth (WYE), Pfizer Inc. (PFE), Sanofi-Aventis SA (SNY) and Chicago Bridge & Iron (CBI).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579.

Here are highlights from Thursday's Analyst Blog:

L-3 Quarterly Results Improve

L-3 Communications (LLL) announced results for its 1st quarter of 2009. LLL reported stable 1st quarter 2009 results with sales up 3.7% year-over-year, net income up 5.3% and fully-diluted EPS up 9.9%.

The U.S. Department of Defense accounted

...